# Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain

> **NCT00236093** · PHASE2 · COMPLETED · sponsor: **Cephalon**

## Conditions studied

- Pain
- Cancer
- Sickle Cell Anemia
- Severe Burns

## Interventions

- **DRUG:** ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])

## Key facts

- **NCT ID:** NCT00236093
- **Lead sponsor:** Cephalon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2006-12
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2014-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00236093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00236093, "Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00236093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*